Zealand Pharma A/S Total Liabilities
Zealand Pharma A/S total liabilities. Based on the latest financial reports, Zealand Pharma A/S (ZEAL) has total liabilities worth Dkr1.63 Billion DKK (≈ $255.21 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Zealand Pharma A/S (ZEAL) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Zealand Pharma A/S (2007–2025)
Total liabilities of Zealand Pharma A/S from 2007 to 2025. This chart illustrates how Zealand Pharma A/S's total liabilities have evolved over time, based on quarterly financial data. Explore Zealand Pharma A/S (ZEAL) long-term investment share to see how much of total assets are deployed in long-term investments.
Zealand Pharma A/S Competitors by Total Liabilities
The table below lists competitors of Zealand Pharma A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanxi Taigang Stainless Steel Co Ltd
SHE:000825
|
China | CN¥28.25 Billion |
|
Beacon Financial Corporation
NYSE:BBT
|
USA | $19.71 Billion |
|
KEYMED BIOSCIENCES -0001
F:64Z
|
Germany | €1.44 Billion |
|
Pattern Group Inc. Series A Common Stock
NASDAQ:PTRN
|
USA | $426.97 Million |
|
Indosat Tbk
JK:ISAT
|
Indonesia | Rp76.15 Trillion |
|
CN LGY.PWR.GR.UNSP.ADR/10
F:6WX0
|
Germany | €176.73 Billion |
|
Koninklijke BAM Groep NV
AS:BAMNB
|
Netherlands | €2.96 Billion |
|
Privia Health Group Inc
NASDAQ:PRVA
|
USA | $650.51 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Zealand Pharma A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ZEAL total assets.
Liquidity & Leverage Metrics
Zealand Pharma A/S Total Liabilities Ratios Explained
Zealand Pharma A/S total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zealand Pharma A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zealand Pharma A/S (2007–2025)
The table below shows the annual total liabilities of Zealand Pharma A/S from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr1.63 Billion ≈ $255.21 Million |
+83.51% |
| 2024-12-31 | Dkr888.86 Million ≈ $139.07 Million |
+129.59% |
| 2023-12-31 | Dkr387.15 Million ≈ $60.57 Million |
-46.52% |
| 2022-12-31 | Dkr723.89 Million ≈ $113.26 Million |
-36.49% |
| 2021-12-31 | Dkr1.14 Billion ≈ $178.33 Million |
+52.48% |
| 2020-12-31 | Dkr747.52 Million ≈ $116.96 Million |
+109.48% |
| 2019-12-31 | Dkr356.84 Million ≈ $55.83 Million |
+214.35% |
| 2018-12-31 | Dkr113.52 Million ≈ $17.76 Million |
-45.63% |
| 2017-12-31 | Dkr208.77 Million ≈ $32.66 Million |
-49.87% |
| 2016-12-31 | Dkr416.43 Million ≈ $65.15 Million |
+8.88% |
| 2015-12-31 | Dkr382.46 Million ≈ $59.84 Million |
+11.20% |
| 2014-12-31 | Dkr343.93 Million ≈ $53.81 Million |
+1017.67% |
| 2013-12-31 | Dkr30.77 Million ≈ $4.81 Million |
-1.97% |
| 2012-12-31 | Dkr31.39 Million ≈ $4.91 Million |
+11.77% |
| 2011-12-31 | Dkr28.08 Million ≈ $4.39 Million |
-35.35% |
| 2010-12-31 | Dkr43.44 Million ≈ $6.80 Million |
+68.67% |
| 2009-12-31 | Dkr25.75 Million ≈ $4.03 Million |
+55.06% |
| 2008-12-31 | Dkr16.61 Million ≈ $2.60 Million |
-20.92% |
| 2007-12-31 | Dkr21.00 Million ≈ $3.29 Million |
-- |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more